{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002744","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2023-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.180641+00:00","generated_at":"2026-06-18T13:01:21.755808+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Kala enrolls first patient in PCED trial, closes $31M private placement","bullets":["Enrolled first patient in CHASE Phase 2b trial of KPI-012 for persistent corneal epithelial defect; top-line data targeted for Q1 2024.","Closed $31.0M private placement in December 2022, extending cash runway into Q1 2025.","Completed sale of EYSUVIS and INVELTYS to Alcon in Q3 2022 to focus on rare eye diseases.","Reported Q4 and FY2022 financial results; specific figures not available in the provided excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002744","json":"https://secwatch.observer/filing/0001558370-23-002744.json","markdown":"https://secwatch.observer/filing/0001558370-23-002744.md","text":"https://secwatch.observer/filing/0001558370-23-002744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023002744/0001558370-23-002744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023002744/kala-20230303x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T13:01:21.755808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"faf0f08f0bb6cc455b9cbd1f21798081703a3573","claim":"KALA BIO, Inc. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On March 3, 2023, Kala Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December 31, 2022 and provided a general business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023002744/0001558370-23-002744-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}